Evidential reasoning-enabled deep learning for reliable treatment outcome prediction in cancer therapy.
Where this comes from
- Record sourced from PubMed, PMID 42114397.
- Also identified by DOI 10.1016/j.artmed.2026.103445.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Treatment outcome prediction plays an important role in realizing personalized cancer therapy. In triple-negative breast cancer (TNBC), neoadjuvant chemotherapy (NAC) is widely used to downstage tumors and improve surgical outcomes. In head and neck cancer (HNC), early prediction of lesion progression can assist treatment planning. However, inter-patient heterogeneity in treatment response and tumor behavior limits the effectiveness of generalized treatment strategies. To address this issue, we developed an evidential reasoning rule-enabled deep neural network (ER<sup>2</sup>-DNN) for reliable outcome prediction in cancer therapy. The ER<sup>2</sup>-DNN combines convolutional neural network (CNN) based image feature extraction with data augmentation, Monte Carlo dropout, test-time augmentation and evidential reasoning rule (ER<sup>2</sup>) fusion for generating uncertainty-aware prediction. Across both TNBC and HNC datasets, the model showed consistent predictive performance with well-calibrated confidence estimates. The ER<sup>2</sup>-DNN provides a framework for supporting individualized oncology decisions through reliable image-based modeling.
Medical subject headings
- Deep Learning
- Triple Negative Breast Neoplasms
- Head and Neck Neoplasms